Amazfit (Balance / Active / T-Rex / Helio) at China, Asia

Zepp Health Corporation (NYSE: ZEPP), the company formerly known as Huami and renamed in February 2021 under founder and chief executive Wang Huang, makes the Amazfit line of budget-tier biometric smartwatches, bands, and rings, recorded in the biometric form factor with the company as Zepp Health, the Amazfit consumer brand as the device line, and the Zepp app and its AI features as model attributes; its historical manufacturing of the Xiaomi Mi Band is an original-design-manufacturer note rather than a separate model line. The Amazfit line spans the Balance, Active, T-Rex, Bip, Cheetah, and Falcon devices plus the Helio Ring and Strap, pairing heart-rate, blood-oxygen, sleep, and stress sensing with genuine AI augmentation including the GPT-backed Zepp Flow voice assistant, the adaptive Zepp Coach, and the Zepp Aura AI sleep features.

On FDA status, Amazfit devices are general-wellness and not FDA-cleared for medical features, with no FDA-cleared ECG app and atrial-fibrillation capability that is PPG-based rather than a cleared ECG path, and although a 2025 meta-analysis reported strong real-world atrial-fibrillation diagnostic accuracy for an Amazfit PPG system, that is published-study validation rather than FDA clearance, a distinction the registry keeps strictly separate. The company illustrates the scale-versus-validation framework, with high volume and real AI breadth but lighter clinical and regulatory validation than Apple or Withings: it reports more than 200 million devices shipped cumulatively to more than 53 million users across 150-plus countries and 2025 revenue of $258.9 million, up 41.8 percent year over year.

Its claim to be the first to fully integrate AI into smartwatches is marketing rather than independently verified, its cumulative unit and user figures are company-reported, and its heart-health framing rides on PPG and a study rather than FDA clearance.